# A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapism

> **NCT03938454** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 36 (actual)

## Conditions studied

- Priapism

## Interventions

- **DRUG:** Crizanlizumab

## Key facts

- **NCT ID:** NCT03938454
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-16
- **Primary completion:** 2023-03-28
- **Final completion:** 2023-11-29
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2026-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03938454

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03938454, "A Study to Evaluate the Safety and Efficacy of Crizanlizumab in Sickle Cell Disease Related Priapism". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03938454. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*